Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

MBX plans to list on the Nasdaq under the symbol MBX. The recent flurry of IPOs adds to the sense that the environment for biotechs seeking to go public after a two-year lull, with a pick-up in ...

Over my forty years or so in and around dealing rooms and financial markets, I have heard many theories as to how to approach that problem and have settled on a process that has worked for me ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

At close: March 20 at 4:00:00 PM EDT Loading Chart for PASG ...

Release Jan. 10 - Passage Bio: The Philadelphia-based genetic medicines company is planning to lay off about 55% of its staff as it pivots from an in-house to outsourced analytical testing model.

Hinduja emphasized that this is an opportune moment for the promoters to bolster the bank's capital base, especially in light of the recent decrease in the bank's share value following the ...

The portfolio historically used to hold 70-90 stocks, but that number spiked to 134 in June 2021 when the strategy increased its exposure to IPOs and private placements. The portfolio is now back ...

IPO content provided by Renaissance Capital LLC, manager of the IPO-focused ETFs (tickers: IPO, IPOs).

After hours: March 21 at 7:27:39 p.m. EDT ...